Assessment of Median and Mean Survival Time in Cancer Clinical Trials

Authors:

Abstract
Clinical trials often report the estimated median survival times to facilitate interpretation. However, the median makes limited use of the survival curve, focusing on the center to the exclusion of other information.1,2 Concerns exist about the median’s stability, as measured by the width of its CIs.3 In trials with few events or limited follow-up, the median survival may not be reached. In contrast, the restricted mean survival time (RMST) provides a clinically interpretable and global summary of survival and may be more stable than the median.3,4 The RMST represents a patient’s expected duration of survival over the follow-up period. For example, if the 5-year RMST of a treatment is 4 years, then a patient receiving that treatment would be expected to survive an average of 4 years over a 5-year follow-up period.
Keywords